HER2-Testung beim Magenkarzinom – Ergebnisse eines deutschen Expertentreffens

Zusammenfassung

Eine valide HER2-Testung ist für die optimale Versorgung von Magenkrebspatienten mit einer HER2-Aktivierung und den richtigen Einsatz einer Erstlinienbehandlung essenziell. Während mittlerweile jedes Mammakarzinom routinemäßig auf den HER2-Status getestet wird, wird die HER2-Testung beim Magenkarzinom noch nicht standardmäßig durchgeführt und erfolgt meist nur auf Anforderung durch den Therapeuten. Eine deutsche interdisziplinäre Expertengruppe hat die Herausforderungen in der HER2-Testung beim Magenkarzinom zum Anlass genommen, um essenzielle Aspekte und Fragestellungen für die praktische Anwendung der HER2-Bestimmung in dieser Indikation aus Sicht von Pathologen und Therapeuten zu adressieren. Die im Manuskript genannten Empfehlungen wurden von allen Teilnehmern konsentiert und entsprechen deren Meinung und langjährigen Erfahrung.

Abstract

Valid HER2 testing is essential for optimal therapy of patients with HER2 positive gastric cancer and the correct use of first-line treatment. While each breast cancer is routinely being tested for the HER2 status, HER2 testing in gastric cancer has still not become part of the routine and is often only done upon request by the therapist. An interdisciplinary German expert group took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication from the perspective of pathologists and therapists. The recommendations made in this manuscript reflect the consensus of all participants and correspond to their opinions and long-term experience.

Schlüsselwörter

Magenkarzinom - HER2-Testung - Konsensus - Qualitätssicherung - Trastuzumab

Key words

gastric cancer - HER2 testing - consensus - quality assurance - trastuzumab

• Literatur

• 1 Fachinformation Herceptin® i.v. (Stand: Juli 2015)
• 2 Horner MJ, Ries LAG, Krapcho M et al. SEER Cancer Statistics Review, 1975–2006. 2009; http://seer.cancer.gov/csr/1975_2006/Zugegriffen :20. November 2015
• 3 Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across fi ve continents: defining priorities to reduce cancer disparities in diff erent geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150
• 4 Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 5 Brien TP, Depowski PL, Sheehan CE et al. Prognostic factors in gastric cancer. Mod Pathol 1998; 11: 870-877
• 6 Chung HC, Bang YJ, Xu JM et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing. ECCO Abstract 6511. 34. Berlin, Germany: 2009
• 7 Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529
• 8 Park DI, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379
• 9 Rüschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-650
• 10 Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-837
• 11 Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278
• 12 Moehler M, Al-Batran SE, Andus T et al. S3-Leitlinie „Magenkarzinom “– Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. (AWMF-Regist.-Nr. 032-009-OL). Z Gastroenterol 2011; 49: 461-531
• 13 Shipley J. In: Yao-Shan F, (Hrsg) Methods in Molecular Biology, Volume 204: Molecular Cytogenetics. Protocols and Applications. Humana Press, John Wiley & Sons, Ltd.; 2002.
• 14 Rüschoff J, Nagelmeier I, Baretton G et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer?. Pathologe 2010; 31: 208-217
• 15 Wolff AC, Hammond ME, Hicks DG et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013
• 16 Warneke V, Behrens HM, Böger C et al. Her2/neu-testing in gastric cancer – evaluating the risk of sampling errors. Ann Oncol 2013; 24: 725-733
• 17 Park SR, Park YS, Ryu MH et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016; 53: 42-50
• 18 Gullo I, Grillo F, Molinaro L et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endoscopy International Open 2015; 03: E165-E170
• 19 Tominaga N, Gotoda T, Hara M et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer 2015; [Epub ahead of print]
• 20 Empfehlungen zur Konsiliar- und Zweitbefundung in der Pathologie des Bundesverbandes Deutscher Pathologen und der Deutschen Gesellschaft für Pathologie. Stand: 3. September 2010. In: Mitglieder-Handbuch. Fassung: 1.1.2011. B 10.0. S 1-4
• 21 Barros-Silva JD, Leitão D, Afonso L et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 487-493
• 22 Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805
• 23 Informationen zu QuiP®:. http://www.pathologie.de/pathologie/quip/ [Zugegriffen: 25. Januar 2016]
• 24 Choritz H, Büsche G, Kreipe H. Study Group HER2 Monitor. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch 2011; 459: 283-289